Drug Trial Radar · NCT07591090
A Phase II Study of AK146D1 Combined With AK112 in Advanced Breast Cancer
Last checked: Nov 19, 2026Latest source record: Jul 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
200
Planned (sponsor's estimate)
Start
Jul 17, 2026
Primary completion
Sep 1, 2027
Study completion Feb 4, 2029
Sponsor
- Lead sponsor
- AkesoIndustry
- Sponsor type
- Industry
- First posted
- May 15, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase II clinical study aimed at evaluating the safety, tolerability, antitumor efficacy, PK and immunogenicity of AK146D1 combined with AK112 in advanced breast cancer.
Conditions
- Advanced Breast Cancer
Interventions
AK146D1 for injectionDrug
AK146D1 for injection is an anti-Trop2/Nectin4 bispecific antibody-drug conjugate.
AK112 InjectionDrug
AK112 Injection is a PD-1/VEGF bispecific antibody.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with dose limiting toxicities (DLTs)Time frame: During the first 3 weeks of treatment in Safety Run-in Phase.
- Number of participants with adverse events (AEs)Time frame: From the time of signing informed consent form through 30 days(for AEs) or 90 days(for SAEs) after the last dose of study drug.
- Objective Response Rate (ORR) assessed by investigator per RECIST v1.1Time frame: Up to approximately 2 years.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.